Progress in Guillain-Barré syndrome

Current Opinion in Neurology

Volumn 14, Issue 5, 2001, Pages 597-604

  Hartung, Hans Peter ^a,b   Kieseier, Bernd C ^a,b   Kiefer, Reinhard ^c  

^a UNIVERSITY OF GRAZ   (Austria)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GANGLIOSIDE ANTIBODY; IMMUNOGLOBULIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; GUILLAIN BARRE SYNDROME; IMMUNE MEDIATED INJURY; IMMUNE RESPONSE; INFECTION; NEUROPATHY; PATHOGENESIS; PLASMAPHERESIS; POLYNEUROPATHY; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

AUTOANTIBODIES; GUILLAIN-BARRE SYNDROME; HUMANS;

EID: 0034798604     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200110000-00008     Document Type: Review

References (54)

1. Guillain-Barré syndrome
2. Pathogenesis of Guillain-Barté syndrome
3. Antibody responses in the Guillain-Barré syndrome
4. Antiglycolipid antibodies in Guillain-Barré syndrome and autoimmune neuropathies
5. The role of anti-glycolipid antibodies in peripheral neuropathies
6. Guillain-Barré syndrome associated with IgG monospecific to ganglioside GD1b
7. Range of cross-reactivity of anti-GM1 IgG antibodies in Guillain-Barré syndrome
8. Autoantibodies to GM1b and GaINAc-GD1a: Relationship to Campylobacter jejuni infection and acute motor axonal neuropathy in China
9. Guillain-Barré syndrome with antibody to a ganglioside, N-acetylgalactosaminyl GD1a
10. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome
11. Rapidly progressive, predominantly motor Guillain-Barré syndrome with anti-GaINAc-GD1a antibodies
12. Guillain-Barré syndrome with IgM antibody to the ganglioside GaINAc-GD1a
13. Ataxic Guillain-Barré syndrome with anti-GQ1b antibody: Relation to Miller-Fisher syndrome
14. Fine specificity of anti-GQ1b IgG and clinical features
15. Anti-GQ1b IgG antibody syndrome: Clinical and immunological range
16. IgG antiganglioside antibodies in Guillain-Barré syndrome with bulbar palsy
17. Antiganglioside antibody in patients with Guillain-Barré syndrome who show bulbar palsy as an initial symptom
18. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal
19. Double agents and breakdown of integrity at the neuromuscular junction in Miller-Fisher syndrome
20. Combined pre- and postsynaptic action of IgG antibodies in Miller-Fisher syndrome
21. Anti-GM1 antibodies can block neuronal voltage-gated sodium channels
22. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside
23. Animal models for autoimmune demyelinating disorders of the nervous system
24. Sequential expression of chemokines in experimental autoimmune neuritis
25. Dynamics of production of MIP-1alpha, MCP-1 and MIP-2 and potential role of neutralization of these chemokines in the regulation of immune responses during experimental autoimmune neuritis in Lewis rats
26. Chemokines and peripheral nerve demyelination
27. Expression and distribution of transcription factor NF-κB and inhibitor IκB in the inflamed peripheral nervous system
28. The role of macrophages in immunemediated damage to the peripheral nervous system
29. Interleukin-18 is induced in acute inflammatory demyelinating polyneuropathy
30. Unusual T cell receptor phenotype V gene usage of γδ T cells in a line derived from the peripheral nerve of a patient with Guillain-Barré syndrome
31. T cell apoptosis in autoimmune diseases: Termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms
32. Mechanisms of immune regulation in the peripheral nervous system
33. Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factor-α
34. IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barré syndrome
35. Guillain-Barré syndrome and Campylobacter jejuni infection
36. Preceding infections, immune factors, and outcome in Guillane-Barré syndrome
37. Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni
38. Molecular characterization of Campylobacter jejuni from patients with Guillain-Barré and Miller-Fisher syndromes
39. The spectrum of antecedent infections in Guillain-Barré syndrome
40. Haemophilus influenzae infection and Guillain-Barré syndrome
41. Infectious origins of and molecular mimicry in Guillain-Barré and Miller-Fisher syndromes
42. Miller-Fisher syndrome and Haemophilus influenzae infection
43. A Campylobacter jejuni gene associated with immune-mediated neuropathy
44. The immunopathogenesis of Miller Fisher syndrome
45. Plasmapheresis and acute Guillain-Barré syndrome
46. Efficiency of plasma exchange in Guillain-Barré syndrome: Role of replacement fluids
47. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome
48. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome
49. CSF filtration is an effective treatment of Guillain-Barré syndrome: Results of a randomized clinical trial
50. An endogenous acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system
51. Drain the roots: A new treatment for Guillain-Barré syndrome?
52. Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome
53. Amplified fragment length polymorphism analysis of Camphylobacter jejuni strains isolated from chickens and from patients with gastroenteritis or Guillain-Barré or Miller Fisher syndrome
54. Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barré syndrome: A pilot study